The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract ...

In the fast-paced world of drug development, time is often the most precious commodity. For biotech companies working on oral ...

Swiss CDMO Lonza is making a move to strengthen and speed up quality control testing with the purchase of French rapid microbiology testing firm Redberry SAS. The acquisition, announced Monday, Oct.

(NEXSTAR) – Over 141,000 bottles of cholesterol medication have been recalled due to “failed dissolution specifications,” suggesting that the drugs did not pass a solubility test, or failed to ...

Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug. At the center of the deal is certepetide, an ...

New brand with proven track record – EMA and FDA-audited mirrored-capability sites in Poland provide an accelerated path from development to commercialization. GDAŃSK & WARSAW-DUCHNICE, ...

GameSpot may get a commission from retail offers. The 1.0 version of Hades 2 is here, along with an assortment of questions and vague pointers about how to actually finish the story. Whether you're ...

According to the latest study from BCC Research, the demand for “Global Market Opportunities and Competitive Landscape for CDMOs” was valued at $128.0 billion in 2023 and is expected to grow from $136 ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Behzad Mahdavi, Ph.D., MBA, NACD.DC, is a Global Commercial Leader in Innovation-Driven, Patient-Centric Strategic Growth in Biopharma. In today’s biopharmaceutical environment, the stakes have never ...

The Netherlands-based Ofichem Group signed a definitive agreement to acquire Avivia, another Netherlands-based company that specializes in formulation development. Ofichem officials say the ...

The U.S. pharmaceutical CDMO market size is expected to be worth around 83.86 billion by 2034, increasing from USD 40.65 billion in 2024, representing a healthy CAGR of 7.51% from 2025 to 2034. The ...